Jon

Jon Edwards, Ph.D. | Non-executive Director

Jon Edwards is a Principal on the investment team at Medicxi, with a primary focus on early-stage opportunities. Prior to Medicxi, Jon worked at Index as an associate and was a life science strategy consultant at ClearView Healthcare Partners. In addition to being a board member for Xenikos, Jon also serves on the boards of Palladio Biosciences, Z-Factor, UltraHuman Ltd, Sydnexis and Impact Biomedicines...

Read more ...

Jake

Jake Simson, Ph.D. | Non-executive Director

Jake Simson is a Principal on the investment team at RA Capital Management, where his primary responsibility is to conduct due diligence on biotechnology companies. Prior to this role, Jake was a Senior Associate on the Landscape Team within the TechAtlas division of RA Capital, where he mapped competitive landscapes in the solid tumor oncology space and...

Read more ...

Jake

Rogier van den Braak, MSc. CPA | Non-executive Director

Rogier van den Braak is CFO at Sanquin with a main focus on strategy, business development and innovation. Prior to this role he held various positions with Sanquin. Before that Rogier served as audit manager at the municipality of Amsterdam. In addition to being a board member for Xenikos, Rogier also serves as a supervisory board member of ETB-BISLIFE and...

Read more ...

Jake

Ypke van Oosterhout, Ph.D. | Executive Director

Ypke van Oosterhout is the founder and CEO of Xenikos B.V. and the pioneering scientist behind T-Guard’s development. Ypke discovered T-Guard while working in the Hematology Department of Radboud University Nijmegen 
Medical Center (the Netherlands) after earning his Masters Degree in biology from the University of Nijmegen. Recognizing T-Guard’s clinical potential...

Read more ...